Malay Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
- Paid Up Capital ₹ 2.50 M
- Company Age 1 Year 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.00 Cr
About Malay Pharma
Malay Pharma Private Limited (MPPL) is a Private Limited Indian Non-Government Company incorporated in India on 16 March 2023 (One year and 11 months 11 days old ). Its registered office is in Patna, Bihar, India.
The Company is engaged in the Paper Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.50 M.
The company currently has active open charges totaling ₹1.00 Cr.
Ragini Rani, Arun Singh, and Ritwik Singh serve as directors at the Company.
Company Details
- Location
Patna, Bihar, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U21002BR2023PTC062024
- Company No.
062024
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Mar 2023
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Patna
Industry
Who are the key members and board of directors at Malay Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ritwik Singh  | Managing Director | 16-Mar-2023 | Current |
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ragini Rani | Director | 16-Mar-2023 | Current |
| Arun Singh | Director | 16-Mar-2023 | Current |
Financial Performance of Malay Pharma.
Enhance accessibility to Malay Pharma's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Malay Pharma?
Unlock access to Malay Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Securebyte Cyber Solutions Private LimitedRitwik Singh is a mutual person
Charges (Loans)
₹10.00 M
₹0
Charges Breakdown by Lending Institutions
- State Bank Of India : 1.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 May 2024 | State Bank Of India | ₹1.00 Cr | Open |
How Many Employees Work at Malay Pharma?
Unlock and access historical data on people associated with Malay Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Malay Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Malay Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.